Volume 5, Number 1, September 2004

Conclusions on the management of heart failure
Karl Swedberg

Activity of the renin-angiotensin-aldosterone system (RAAS) is increased in heart failure. Agents which act on the RAAS can be expected to benefit these patients. Recent trials which have furthered our understanding of drugs which are of benefit in heart failure – angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers and aldosterone antagonists – are discussed. It is desirable to use multiple agents for best results in patients with heart failure. New European Society of Cardiology guidelines on the management of heart failure are expected later this year.

JRAAS 2004;5:S34-S36.

View full PDF article (open in new window)
Email this article

Right click on this DOI link and copy link to cite this article (What is a DOI link?)